Results 261 to 270 of about 37,077 (282)
Some of the next articles are maybe not open access.
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, 1999Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
D M, Segal, G J, Weiner, L M, Weiner
openaire +2 more sources
Introduction: bispecific antibodies
Journal of Immunological Methods, 2001D M, Segal, G J, Weiner, L M, Weiner
openaire +2 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources
Bispecific Antibody Therapy in Hemophilia
New England Journal of Medicine, 2017Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire +2 more sources
Bispecific Antibodies for Cancer Therapy
Immunotherapy, 2009Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
openaire +2 more sources
Bispecific antibodies catch cancer neoantigens
Nature Reviews Drug Discovery, 2021openaire +2 more sources